Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Lasse H Jakobsen, Fredrik Ellin, Knut B Smeland, Tove Wästerlid, Jacob H Christensen, Judit M Jørgensen, Pär L Josefsson, Andreas K Øvlisen, Harald Holte, Yngvild N Blaker, Jacob H Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, Karin E Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J Maurer, Thomas M Habermann, Kevin W SongKatie Y Zhu, Alina S Gerrie, Chan Y Cheah, Tarec C El-Galaly

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

1 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
ISSN0963-1860
DOI
StatusE-pub ahead of print - 4 feb. 2020

Fingeraftryk Dyk ned i forskningsemnerne om 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater

    Jakobsen, L. H., Ellin, F., Smeland, K. B., Wästerlid, T., Christensen, J. H., Jørgensen, J. M., Josefsson, P. L., Øvlisen, A. K., Holte, H., Blaker, Y. N., Grauslund, J. H., Bjørn, J., Molin, D., Lagerlöf, I., Smedby, K. E., Colvin, K., Thanarajasingam, G., Maurer, M. J., Habermann, T. M., ... El-Galaly, T. C. (2020). Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology. https://doi.org/10.1111/bjh.16425